Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SP-103

Other · developed by Scilex Pharmaceuticals

Phase 2 Most advanced trial (none active)

SCLX Developer

1 Registered trials

What is SP-103?

SP-103 is an investigational drug studied in Moderate to Severe Acute Lower Back Pain.

At a glance

Drug type: Other
Therapy area: Musculoskeletal
Developer: Scilex Pharmaceuticals, Inc. (SCLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05096494	Phase 2	Moderate to Severe Acute Lower Back Pain	Completed	SCLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Moderate to Severe Acute Lower Back Pain

More from Scilex Pharmaceuticals

SP-102 Phase 3

Sources

ClinicalTrials.gov NCT05096494

Updated Oct 3, 2026. Something wrong or missing? Report it on the SCLX page.

Follow SCLX, the company behind SP-103

See SCLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SCLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z